Neurologic Complications Seen in Hospitalized COVID-19 Patients
Neurologic disorders tied to increased risk for in-hospital mortality.
General Psychiatry
Most Users Report Cannabidiol Use for Treatment of Diagnosable Conditions
Psychiatric, orthopedic, and sleep issues most commonly cited in a Reddit forum
MPR Weekly Dose Podcast Episode 54
This week: News of another vaccine trial being put on hold; A trial assessing hyperimmue globulin beings; An NDA for IV tramadol is rejected; FDA Committees vote on novel schizophrenia and bipolar I disorder therapy; And a first approval for Ebola.
Wakix Indication Expanded to Include Cataplexy Treatment
The approval was based on data from two phase 3 trials (HARMONY CTP and HARMONY 1) that evaluated the efficacy and safety of pitolisant for the treatment of cataplexy.
FDA Committees Vote on Novel Therapy for Schizophrenia, Bipolar I Disorder
ALKS 3831 is composed of samidorphan, a mu-opioid receptor antagonist, which is co-formulated with the established antipsychotic agent, olanzapine, in a single bilayer tablet.
Idiopathic Hypersomnia Study Evaluating Xywav Meets End Points
The multicenter, double-blind, placebo-controlled phase 3 study evaluated the efficacy and safety of Xywav in adults with idiopathic hypersomnia.
Mortality Risk Up With Newer Antipsychotic Use for Depression
Risk up for nonelderly adults with augmentation with newer antipsychotic versus second antidepressant.
MPR Weekly Dose Podcast Episode 52
This week we cover new Moderna vaccine results; Boxed Warning for benzodiazepines; Point-of-care COVID-19 antibody test; Diphenhydramine overdoses linked to TikTok ‘challenge’; And FDA grants Nucala new approval. Also we look at this week’s developments in drugs in the pipeline.
FDA Requires Boxed Warning Update for Benzodiazepines
Benzodiazepines are widely used to treat a variety of conditions including anxiety disorders, insomnia and seizures.
Transdermal Cannabidiol Gets Orphan Drug Status for 22q11.2 Deletion Syndrome
The efficacy and safety of Zygel is being evaluated in the INSPIRE study.
